In murine models, we have shown that systemic injection of MSCs expressing full-length human TRAIL leads to a reduction in subcutaneous tumor growth and reduced, or indeed eliminated, lung metastases [10], and attenuates malignant pleural mesothelioma development [13]. Here, TNFSF10 is linked to malignant pleural mesothelioma.